

## FREEDOM OF INFORMATION REQUEST

RF23-683

**We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested. Please see the responses in bold below.**

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

CAPOX (Capecitabine with Oxaliplatin)	<b>0</b>
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)	<b>&lt;5*</b>
Lonsurf (Trifluridine - tipiracil)	<b>0</b>
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<b>0</b>
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<b>0</b>
Any other systemic anti-cancer therapy	<b>8</b>
Palliative care only	<b>Unknown**</b>

2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

Nivolumab monotherapy or combination with Ipilimumab	<b>4</b>
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<b>0</b>
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<b>2</b>
Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	<b>6</b>
Any other systemic anti-cancer therapy	<b>34</b>
Palliative care only	<b>Unknown**</b>

3. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:

Paclitaxel in combination with a platinum-based compound	<b>14</b>
Platinum-based therapy alone (cisplatin or carboplatin)	<b>8</b>
Bevacizumab in combination with paclitaxel and carboplatin	<b>0</b>
Olaparib	<b>7</b>
Olaparib + Bevacizumab	<b>1</b>
Niraparib	<b>8</b>
Rucaparib	<b>3</b>

4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:

- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatments

**We are unable to answer this question as this data is not recorded in the ARIA e-prescribing pharmacy system**

5. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

<b>Project Short title</b>	<b>IRAS Number</b>	<b>Project site status</b>	<b>Recruited (org)</b>
<b>ATHENA - a first line ovarian cancer maintenance trial.</b>	<b>240011</b>	<b>Closed to recruitment - in follow up</b>	<b>2</b>
<b>ICON9</b>	<b>231108</b>	<b>Closed to recruitment - in follow up</b>	<b>4</b>
<b>PROTECTOR</b>	<b>237992</b>	<b>Open</b>	<b>7</b>

\* In some circumstances EKHUFT are unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

\*\* This data is not recorded in ARIA e-prescribing pharmacy system

(DATE OF RESPONSE: 14 NOVEMBER 2023)

